| SIGHT Stock | | | EUR 0.31 0.01 3.13% |
Chairman
Dr. Bernard Gilly is Executive Chairman of the Board, Chief Executive Officer and CoFounder of Gensight Biologics SA. He was the Chairman and CEO of Fovea Pharmaceuticals, a biotech company he founded in 2005 and which he sold in 2009 to Sanofi, and then became Senior VicePresident of the Ophthalmology Division of Sanofi until March 2012. Prior to Fovea, he was a Partner at Sofinnova Partners from 2000 to November 2005. He founded and invested in several companies, including Sequoia Pharmaceuticals, Faust Pharmaceuticals and Cellzome . Prior to joining Sofinnova, he served as President and CEO of Transgene and before that, he spent six years as VP RD at PasteurMerieuxConnaught, the vaccine company that since then became Sanofi Pasteur. He was managing scientists and development engineers in three facilities and was a member of the Executive Committee of the group.
| Age | 66 |
| Professional Marks | Ph.D |
| Phone | 33 1 76 21 72 20 |
| Web | https://www.gensight-biologics.com |
Gensight Biologics Management Efficiency
The company has return on total asset
(ROA) of
(0.3876) % which means that it has lost $0.3876 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(1.719) %, meaning that it generated substantial loss on money invested by shareholders. Gensight Biologics' management efficiency ratios could be used to measure how well Gensight Biologics manages its routine affairs as well as how well it operates its assets and liabilities.
Gensight Biologics SA has accumulated 12.1
M in total debt with debt to equity ratio
(D/E) of 14.4, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Gensight Biologics has a current ratio of 3.58, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Gensight Biologics until it has trouble settling it off, either with new capital or with free cash flow. So, Gensight Biologics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Gensight Biologics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Gensight to invest in growth at high rates of return. When we think about Gensight Biologics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 1 records | CHAIRMAN Age |
| Michel Rosen | DBV Technologies SA | 68 |
GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. GenSight Biologics S.A. was founded in 2012 and is headquartered in Paris, France. GENSIGHT BIOLOGICS is traded on Paris Stock Exchange in France. Gensight Biologics SA (SIGHT) is traded on Euronext Paris in France and employs 44 people.
Management Performance
Gensight Biologics Leadership Team
Elected by the shareholders, the Gensight Biologics' board of directors comprises two types of representatives: Gensight Biologics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Gensight. The board's role is to monitor Gensight Biologics' management team and ensure that shareholders' interests are well served. Gensight Biologics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Gensight Biologics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Serge Picaud, Scientific Board | |
| Scott Jeffers, Chief Officer | |
| Clothilde Caillet, Director Communication | |
| Bernard Gilly, Chairman of the Board, CEO, Co-Founder | |
| Pr Roska, Scientific Board | |
| Thomas Gidoin, Chief Officer | |
| JoseAlain MD, Vice Founder | |
| Prof Cepko, Scientific Board | |
Gensight Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Gensight Biologics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Additional Tools for Gensight Stock Analysis
When running Gensight Biologics' price analysis, check to
measure Gensight Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gensight Biologics is operating at the current time. Most of Gensight Biologics' value examination focuses on studying past and present price action to
predict the probability of Gensight Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gensight Biologics' price. Additionally, you may evaluate how the addition of Gensight Biologics to your portfolios can decrease your overall portfolio volatility.